Niagen Bioscience, Inc.
NAGE· Nasdaq
NAGENiagen Bioscience, Inc.
Filed Mar 12, 2021 · 10-K · 71 days after period end · 0001654954-21-002692
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 |
|---|---|---|---|---|
| Revenue | $15.45M | $13.09M | $9.07M | $7.53M |
| Net Income | -$6.10M | -$8.85M | -$8.22M | -$8.82M |
| EPS Diluted | — | — |
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
| — |
| -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Mar 12, 2021 · 71 d after period end
